Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2006 1
2007 3
2008 2
2009 1
2011 3
2012 3
2013 4
2014 3
2015 7
2016 6
2017 13
2018 8
2019 4
2020 4
2021 7
2022 5
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Need for change in cancer follow-up.
Vistad I, Bjørge L, Skeie-Jensen T. Vistad I, et al. Tidsskr Nor Laegeforen. 2020 Apr 20;140. doi: 10.4045/tidsskr.20.0281. Print 2020 Apr 21. Tidsskr Nor Laegeforen. 2020. PMID: 32323956 Free article. English, Norwegian. No abstract available.
Follow-up routines in gynecological cancer - time for a change?
Vistad I, Moy BW, Salvesen HB, Liavaag AH. Vistad I, et al. Acta Obstet Gynecol Scand. 2011 Jul;90(7):707-18. doi: 10.1111/j.1600-0412.2011.01123.x. Epub 2011 Apr 15. Acta Obstet Gynecol Scand. 2011. PMID: 21382018 Free article. Review.
Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer.
Vilming B, Fallås Dahl J, Bentzen AG, Ingebrigtsen VA, Berge Nilsen E, Vistad I, Dørum A, Solheim O, Bjørge L, Zucknick M, Aune G, Lindemann K. Vilming B, et al. Among authors: vistad i. Int J Gynecol Cancer. 2023 Dec 4;33(12):1898-1905. doi: 10.1136/ijgc-2023-004484. Int J Gynecol Cancer. 2023. PMID: 38000795 Free PMC article.
Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.
van Leeuwen M, Kieffer JM, Young TE, Annunziata MA, Arndt V, Arraras JI, Autran D, Hani HB, Chakrabarti M, Chinot O, Cho J, da Costa Vieira RA, Darlington AS, Debruyne PR, Dirven L, Doege D, Eller Y, Eichler M, Fridriksdottir N, Gioulbasanis I, Hammerlid E, van Hemelrijck M, Hermann S, Husson O, Jefford M, Johansen C, Kjaer TK, Kontogianni M, Lagergren P, Lidington E, Lisy K, Morag O, Nordin A, Al Omari ASH, Pace A, De Padova S, Petranovia D, Pinto M, Ramage J, Rammant E, Reijneveld J, Serpentini S, Sodergren S, Vassiliou V, Leeuw IV, Vistad I, Young T, Aaronson NK, van de Poll-Franse LV; EORTC QLG. van Leeuwen M, et al. Among authors: vistad i. J Cancer Surviv. 2023 Aug;17(4):1111-1130. doi: 10.1007/s11764-021-01160-1. Epub 2022 Jan 27. J Cancer Surviv. 2023. PMID: 35088246 Clinical Trial.
74 results